echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ganle Pharmaceutical Mendong insulin received a registered approval of Indonesian API

    Ganle Pharmaceutical Mendong insulin received a registered approval of Indonesian API

    • Last Update: 2021-01-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On 7 January, Gan Li Pharmaceuticals announced that it had received a registration approval from the Indonesian Drug Administration for the registration of mendon insulin API (batch number: RG.01.01.32.322.12.20.01214/H).
    winter insulin raw materials can be used for filling the production of gate winter insulin injection, gate winter insulin injection is a quick-acting insulin similar products, also known as meal insulin, after injection can be quickly absorbed, can be injected immediately before or after meals, to bring convenience to patients.
    Compared with soluble human insulin, menwine insulin after injection faster, shorter duration of action, more in line with the human body after meal physiological insulin secretion mode, close to the meal injection, application is more convenient, can significantly improve blood sugar after meals, so menwine insulin injection has become a particularly important insulin in diabetes treatment.
    Indonesia, with a population of 262 million in Southeast Asia, is the world's fourth most populous country with a per capita GDP of US$3,894 (international exchange rate in 2018), and has 10.7 million diabetes cases among adults aged 20-79, ranking seventh in the world (IDF2019).
    currently, in Indonesia, the main suppliers of mendon insulin injections are No.
    's Mendon insulin product NovoRapid?, will have global sales of approximately DKK 18.06 billion in 2019 (NovoRapid?
    as of September 30, 2020, the company has invested approximately 103 million yuan in its mendong insulin research and development program.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.